Assess and review patients’ hemoglobin (Hgb) and transfusion record prior to each administration1
- If an RBC transfusion occurred prior to dosing, use the pretransfusion Hgb for dose evaluation
REBLOZYL dosing information
REBLOZYL dose titration for response1
| REBLOZYL Dosing recommendation* |
|
| Starting dose | 1 mg/kg every 3 weeks |
 Dose increases for insufficient response at initiation of treatment |
|
| No reduction in RBC transfusion burden after at least 2 consecutive doses (6 weeks) at the 1 mg/kg starting dose |
|
| No reduction in RBC transfusion burden after 3 consecutive doses (9 weeks) at |
|
|
Dose modifications for predose Hgb levels or rapid Hgb rise |
|
| Predose Hgb is ≥11.5 g/dL in the absence of transfusions |
|
Increase in Hgb >2 g/dL within 3 weeks in the absence of transfusions and
|
|
*Do not increase the dose if the patient is experiencing an adverse reaction.
- Overall, 53% of patients in the BELIEVE trial had their dose increased to 1.25 mg/kg (46% REBLOZYL, n = 223; 66% placebo, n = 109)1
Dose increases in the event of loss of response1
- A dose increase to 1.25 mg/kg may occur at any time during treatment after patients have received at least 2 consecutive doses of 1 mg/kg
- Do not increase the dose beyond the maximum dose of 1.25 mg/kg
Discontinue treatment if no reduction in transfusion burden is observed1
- Discontinue REBLOZYL if a patient does not experience a decrease in transfusion burden after 3 doses (9 weeks of treatment) at the maximum dose level or if unacceptable toxicity occurs at any time
If a planned administration of REBLOZYL is delayed or missed, administer REBLOZYL as soon as possible and continue dosing as prescribed, with at least 3 weeks between doses1
REBLOZYL dosing modifications for adverse reactions1
| REBLOZYL Dosing recommendation* |
|
| Grade 3 or 4 hypersensitivity reactions |
|
| Other Grade 3 or 4 adverse reactions |
|
*Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, and Grade 4 is life-threatening.
Instructions for subcutaneous administration
REBLOZYL is administered subcutaneously and is available in 2 vial sizes (25 mg and 75 mg)1
- Prior to injection, allow solution to reach room temperature for a more comfortable injection
REBLOZYL should be reconstituted and administered by a healthcare professional1
Step 1
Verify correct dose for the patient1
- Calculate the exact total dosing volume of 50 mg/mL solution required for the patient
Step 2
Plan and prep for injection1
- Slowly withdraw the dosing volume of the reconstituted REBLOZYL solution from the single-dose vial(s) into a syringe
- Divide doses requiring larger reconstituted volumes (ie, >1.2 mL) into separate similar volume injections and inject into separate sites
Step 3
Subcutaneous administration1
- If multiple injections are required, use a new syringe and needle for each SC injection
- Administer the SC injection into the upper arm, thigh, and/or abdomen
NOTE: Discard any unused portion. Do not pool unused portions from the vials.
Do not administer more than 1 dose from a vial.1
- Do not mix with other medications
Sample calculation for SC administration of REBLOZYL1
- Adult male aged 30 years and weighing 197 pounds (89 kg)
- 1 mg of REBLOZYL per 1 kg = 89 mg starting dose
Total volume of reconstituted solution needed to administer 89 mg: 1.78 mL
| Number of vials | REBLOZYL | Concentration after reconstitution | Solution needed for administration | Milligrams in solution |
|---|---|---|---|---|
| 1 | 75 mg vial | 75 mg/1.5 mL (50 mg/mL) |
Use 1.5 mL | 75 mg |
| 1 | 25 mg vial | 25 mg/0.5 mL | Use 0.28 mL | 14 mg |
| Total volume needed 1.78 mL | 89 mg | |||
Doses with reconstituted volumes larger than 1.2 mL should be divided into separate, similar-volume syringes for injection and injected into separate sites (upper arm, thigh, and/or abdomen)
Injection 1: 0.89 mL – upper arm
Injection 2: 0.89 mL – thigh or abdomen
REBLOZYL dosing and administration video
